Table 6 Univariate analysis of risk factors for RFS and OS

Age (≥ 60 vs. < 60 years)

1.192

0.706–2.014

0.511

1.142

0.654–1.993

0.641

Sex (female vs. male)

1.681

0.902–3.131

0.102

1.694

0.884–3.246

0.112

CCI^a (≥ 2 vs. < 2)

1.293

0.585–2.858

0.526

0.991

0.392–2.503

0.984

cTNM stage^b (III vs. II)

1.149

0.520–2.538

0.731

0.974

0.437–2.167

0.948

Surgical procedure (laparoscopy vs. open)

0.816

0.482–1.380

0.448

0.911

0.522–1.589

0.742

Number of lymph node dissection (≤ 22 vs. < 22)

0.951

0.563–1.606

0.850

1.060

0.606–1.855

0.838

Tumor size^c (≥ 4 vs. < 4 cm)

2.621

1.491–4.606

0.001

3.792

2.001–7.186

< 0.001

Histological type (undifferentiated vs. differentiated)

1.695

0.911–3.153

0.096

1.801

0.922–3.520

0.085

Lymph-vascular invasion (yes vs. no)

3.175

1.850–5.447

< 0.001

3.234

1.829–5.718

< 0.001

Nerve invasion (yes vs. no)

1.973

1.160–3.356

0.012

1.814

1.037–3.174

0.037

Margin of resection (R1 vs. R0)

3.457

1.718–6.957

0.001

3.201

1.542–6.642

0.002

Postoperative complications (yes vs. no)

1.351

0.738–2.476

0.330

1.279

0.668–2.448

0.458

Clinical response of RECIST^d (PD or SD vs. PR or CR)

7.755

3.761–15.991

< 0.001

8.506

3.787–19.104

< 0.001

Tumor regression grade^e (2 or 3 vs. 1 or 0)

2.059

0.881–4.810

0.095

2.300

0.908–5.829

0.079

ypTNM stage^b (III or IV vs. PCR or I or II)

6.841

3.497–13.381

< 0.001

7.565

3.519–16.264

< 0.001

Postoperative adjuvant chemotherapy (no vs. yes)

2.080

1.132–3.825

0.018

2.350

1.259–4.384

0.007